RE:Soleus holdingsOne of these was labeled wrong -- it's BioAtla. This company just went public and has a market cap of $1.6bil. It's a cancer stock -- they make a biologic that attaches to tumors based on the acidity difference of the membrane and then switches on. So it's sort of like a homing device that allows for other drugs and vehicles (ADCs, CAR-Ts, others) to just attache to the tumor and not healthy tissues based on "switching" it on. They call them "Conditionally Active Biologics", CABs.
So a way to have much lower toxicity and treat for longer. Sound familiar?
They're leading drugs are in Phase 2's and target things like sarcoma, ovarian, etc.. The rest is all pre-clinical or about to go Phase 1. So really, they just have two trials just entering Phase 2 and 3-4 behind that. Each is a different drug or mechanism attached to their CAB.
The Soleus guys are on the board. So lends a bit more to the thought that these guys really do know the cancer space quite well and have chosen to invest in the SORT1+ platform. Credibility there with that. I notice the other big holders of BioAtla are Baker Brothers, HRM and assorted other healthcare specialists. Now they'll have SORT1+ to chat about at their cocktail parties!
Wino115 wrote: I think Spatrap mentioned ESSA PHarma (EPIX) a few weeks ago (prostate cancer drug). That's one of Soleus larger holdings. It's up 5x since summer. Others are Biotla (top holding Dec20), Lantheus, Iveric bio, C4 Therapeutics, Alpine Immune.
Looks like they manage around $700mil in US fund and positions vary from $10-$40mil.